Anti-drug antibody news
What is the immunogenic profile of a drug and what to do about it? At Pharmetheus, we have, together with the whole team, reviewed with
What is the immunogenic profile of a drug and what to do about it? At Pharmetheus, we have, together with the whole team, reviewed with
We cannot wait to meet you at PAGE next week! Many of our team members will be coming to the conference in person, and will
Pharmetheus is a proud partner of the SweDeliver (The Swedish Drug Delivery Center) initiative that recently was identified as being critical to the technological development
Tomas Salmonson, formerly occupying senior positions at the Medical Products Agency, Sweden, recently joined Pharmetheus’ Board of Directors, and we couldn’t be prouder. Tomas’ many
We are happy to have Joakim Hellner on board as an Associate Data Programmer. His experience includes data processing, data visualization and full stack web
Are you interested in a Ph.D. position linking Pharmetheus with two leading centers, Sanofi and the School of Pharmacy at Aix Marseille University? Join us
Will you attend Page 2022 and would benefit from additional insights on a) leveraging in vitro data or b) interpreting covariate effects in models? We
It is our pleasure to introduce Anna Mc Laughlin, Associate Consultant, who recently joined Pharmetheus. Anna’s experience includes pharmacometrics and model-informed precision dosing in oncology
In 2021, the FDA granted an accelerated approval to tepotinib for metastatic non-small cell lung cancer. Earlier on, tepotinib had been approved for the treatment
Pharmetheus is delighted to count Birgit Köster Hoffman among its new Board members. Birgit, an experienced international CEO and CFO, has developed an expertise as
Pharmetheus offers consulting services focused on the application of quantitative approaches to support drug development decisions..